NCT05066516View on ClinicalTrials.gov

The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 25, 2020

Primary Completion Date

August 18, 2020

Study Completion Date

October 18, 2020

Conditions
Diabetes Mellitus
Interventions
DRUG

FCDP, dapagliflozin 10mg/linagliptin 5 mg or co-administration of a single dose of dapagliflozin and linagliptin

FCDP, dapagliflozin 10mg/linagliptin 5 mg or ICs, co-administration of a single dose of dapagliflozin and linagliptin

Trial Locations (1)

02841

Korea University Anam Hospital, Seoul

All Listed Sponsors
lead

Korea University Anam Hospital

OTHER

NCT05066516 - The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects | Biotech Hunter | Biotech Hunter